189 related articles for article (PubMed ID: 31379370)
1. [LHRH analogs: current role in early and advanced breast cancer treatment of premenopausal patients.].
Fabi A; Catania G
Recenti Prog Med; 2019; 110(7):347-355. PubMed ID: 31379370
[TBL] [Abstract][Full Text] [Related]
2. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
4. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Michaud LB; Buzdar AU
Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
[TBL] [Abstract][Full Text] [Related]
5. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
6. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
Chlebowski RT; Pan K; Col NF
Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
[TBL] [Abstract][Full Text] [Related]
7. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
8. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
Tancredi R; Furlanetto J; Loibl S
Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.
Montemurro F; Del Mastro L; De Laurentiis M; Puglisi F
Expert Rev Anticancer Ther; 2016; 16(2):211-8. PubMed ID: 26634955
[TBL] [Abstract][Full Text] [Related]
13. [LHRH analogs in adjuvant endocrine therapy for pre-menopausal localized breast cancers: Ending the controversy for novel guidelines?].
Daguenet E; Jmour O; Vallard A; Guy JB; Jacquin JP; Méry B; Magné N
Bull Cancer; 2019 Apr; 106(4):342-353. PubMed ID: 30853114
[TBL] [Abstract][Full Text] [Related]
14. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
15. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
17. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.
Klijn JG; Blamey RW; Boccardo F; Tominaga T; Duchateau L; Sylvester R;
J Clin Oncol; 2001 Jan; 19(2):343-53. PubMed ID: 11208825
[TBL] [Abstract][Full Text] [Related]
18. The relationship between serum E2 levels and recurrence in premenopausal, ER-positive breast cancer patients: A retrospective study.
Takuwa H; Saji S; Takada M; Takahara S; Yamauchi A
Breast Dis; 2018; 37(4):185-190. PubMed ID: 29578459
[TBL] [Abstract][Full Text] [Related]
19. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
20. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Pistelli M; Mora AD; Ballatore Z; Berardi R
Curr Oncol; 2018 Apr; 25(2):e168-e175. PubMed ID: 29719441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]